Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Trial Profile

Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Sumatriptan (Primary) ; Sumatriptan
  • Indications Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPASS
  • Sponsors Avanir Pharmaceuticals; OptiNose
  • Most Recent Events

    • 11 Jun 2017 Results (n=259) assessing the complex relationships among treatment, pain, and disability using bivariate latent curve models, presented at the 59th Annual Scientific Meeting of the American Headache Society.
    • 11 Jun 2017 Results of bifactor analysis (n=259) comparing migraine severity of AVP-825 versus oral Sumatriptan, presented at the 59th Annual Scientific Meeting of the American Headache Society.
    • 11 Jun 2017 Results (n=259) presented at the 59th Annual Scientific Meeting of the American Headache Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top